Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines-Reference-Cited by-同舟云学术

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Published:2023-06 Issue:6 Volume:86 Page:574-583
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Shaw Robert H.,Greenland Melanie,Stuart Arabella S.V.,Aley Parvinder K.,Andrews Nick J.,Cameron J. Claire^ORCID,Charlton Sue^ORCID,Clutterbuck Elizabeth A.,Collins Andrea M.,Darton Tom,Dinesh Tanya,Duncan Christopher J.A.,Faust Saul N.,Ferreira Daniela M.,Finn Adam,Goodman Anna L.,Green Christopher A.,Hallis Bassam,Heath Paul T.,Hill Helen,Lambe Teresa,Libri Vincenzo^ORCID,Lillie Patrick J.,Morey Ella,Mujadidi Yama F.,Payne Ruth,Plested Emma L.,Provstgaard-Morys Samuel,Ramasamy Maheshi N.,Ramsay Mary,Read Robert C.,Robinson Hannah,Screaton Gavin R.,Singh Nisha^ORCID,Turner David P.J.,Turner Paul J.,White Rachel,Nguyen-Van-Tam Jonathan S.,Liu Xinxue,Snape Matthew D.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference13 articles.

1. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis [Internet]. Vol. 22(no. 9); 2022 [cited 2022 Oct 3], p. 1293–302. Available from: 〈http://www.thelancet.com/article/S1473309922003206/fulltext〉.

2. Coronavirus (COVID-19) vaccinations – statistics and research [internet];Our World Data,2021

3. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial;Stuart;Lancet,2021

4. University of Oxford. COM-CoV3 Study website [Internet]; 2021 [cited 2022 Oct 23]. Available from: 〈https://comcovstudy.org.uk/about-com-cov3〉.

5. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial;Shaw;Lancet Respir Med,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06

2. Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study;Scientific Reports;2024-04-18

3. Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients;Journal of Medical Virology;2024-03

4. Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine;Vaccines;2023-11-15

5. Safety and immunogenicity of COReNAPCIN^®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial;2023-11-02